Please login to the form below

Not currently logged in
Email:
Password:

Revolution Medicines appoints Dr Stephen Kelsey

He joins the firm from Onkaido Therapeutics

Dr Stephen KelseyRevolution Medicines has appointed Dr Stephen Kelsey as its senior leader in a role that will see him focus on advancing medical agendas to aid cancer patients.

Most recently president at Onkaido Therapeutics, Kelsey’s specialty lies within oncology and development.

He said: “Revolution Medicines uses a novel approach to drug discovery that enables it to tackle promising cancer targets that have been difficult to access by convention means.

“I’m impressed with the quality of the company’s research team, founders and advisors, and am keen to help bring the next generation of transformational therapeutics to cancer patients.”

Prior to his time at Onkaido Therapeutics, Kelsey has served in several senior positions at Medivation, Generon and Genentech, where he held the role of vice president, haematology and oncology.

Mark Goldsmith, president and chief executive officer of Revolution Medicines, said: “Steve has had a distinguished career in oncology as both an academic clinician and a drug development executive in the biotechnology industry.

“He is superbly positioned to help us by deliver great benefit to cancer patients by advancing our lead programmes and creating a sustainable product pipeline that harnesses frontier oncology targets.”

31st March 2017

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
KVA

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...